Nexalin Technology (Nexalin Technology) EBIT : $-6.03 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Nexalin Technology EBIT?

Nexalin Technology's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-1.07 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.03 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Nexalin Technology's annualized ROC % for the quarter that ended in Mar. 2024 was -1,030.22%. Nexalin Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -14,085.25%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Nexalin Technology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -250.25%.

Nexalin Technology EBIT Historical Data

The historical data trend for Nexalin Technology's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexalin Technology EBIT Chart

Nexalin Technology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBIT

-3.33

-6.00

-1.83

-5.70

Nexalin Technology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial									-0.78	-0.82	-2.29	-1.85	-1.07

Competitive Comparison of Nexalin Technology's EBIT

For the Medical Devices subindustry, Nexalin Technology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nexalin Technology's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nexalin Technology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Nexalin Technology's EV-to-EBIT falls into.

Nexalin Technology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.03 Mil.

Nexalin Technology (NAS:NXL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Nexalin Technology's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-4.296 * ( 1 - 0% )	/	( (0.413	+	0.421)	/ 2 )
=	-4.296	/	0.417
=	-1,030.22 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.632	-	0.271	-	( 2.948	-	max(0, 0.425	-	3.43	+	2.948	))
=	0.413

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.834	-	0.357	-	( 2.144	-	max(0, 0.507	-	2.563	+	2.144	))
=	0.421

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Nexalin Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-4.296	/	( ( (0 + max(0.061, 0))	+	(0 + max(-0.088, 0)) )	/	2 )
=	-4.296	/	( ( 0.061	+	0 )	/	2 )
=	-4.296	/	0.0305
=	-14,085.25 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.009	+	0.156	+	0.317)	-	(0.271	+	0	+	0.15)
=	0.061

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.004	+	0.154	+	0.261)	-	(0.357	+	0	+	0.15)
=	-0.088

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Nexalin Technology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-6.031	/	2.410
	=	-250.25 %

Nexalin Technology EBIT Related Terms

Thank you for viewing the detailed overview of Nexalin Technology's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Nexalin Technology (Nexalin Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nexalin Technology Inc (NAS:NXL) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

1776 Yorktown, Suite 550, Houston, TX, USA, 77056

Website

https://www.nexalin.com

Nexalin Technology Inc design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy.

Executives

Marilyn Elson	10 percent owner, officer: Ms. Elson serves as CFO	32 CAMLET COURT, ROSELAND NJ 07068
Rick Morad	director	6331 CHAGRIN RIVER ROAD, BENTLEYVILLE OH 44022
Mark White	director, officer: President/CEO	1776 YORKTOWN STREET, SUITE 550, HOUSTON TX 77056
David Owens	director, officer: Chief Medical Officer	4545 HARRIS TRAIL NW, ATLANTA GA 30327
Alan Kazden	director	3435 CONSUELO DRIVE, CALABASAS CA 91302
Leonard Osser	other: Spouse
Ben Hu	director	7021 EDGERTON ROAD, NORTH ROYALTON OH 44133